AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05383820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: The first group will be administered with Placebo (calcined magnesia), the second group with Ketorolac and the third group with Paracetamol, for all groups the medication will be one capsule every 6 hours for 5 days all study subjects will be sampled Gingival Crevicular Fluid (LGC), Visual Analogue Pain Scale (APS) and Intermolar Space (IS).
Study NCT05383820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: The first group will be administered with Placebo (calcined magnesia), the second group with Ketorolac and the third group with Paracetamol, for all groups the medication will be one capsule every 6 hours for 5 days all study subjects will be sampled Gingival Crevicular Fluid (LGC), Visual Analogue Pain Scale (APS) and Intermolar Space (IS).
Study NCT05383820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketorolac
Description: The first group will be administered with Placebo (calcined magnesia), the second group with Ketorolac and the third group with Paracetamol, for all groups the medication will be one capsule every 6 hours for 5 days all study subjects will be sampled Gingival Crevicular Fluid (LGC), Visual Analogue Pain Scale (APS) and Intermolar Space (IS).
Study NCT05988814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX treatment
Description: Treatment with FOLFIRINOX3 will be administered with a maximum of 16 courses divided into two 8-course doses.~Maintenance treatment (folinic acid/calcium levofolinate + 5-FU) will be administered until progression
Study NCT05464095 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mHealth Intervention
Description: The Health Insurance Portability and Accountability Act (HIPPA) compliant texting platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to the mHealth platform via cellular network. Participants assigned to the texting arm will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule, which is defined at enrollment. These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
Study NCT05464095 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Usual Care
Description: The HIPPA-compliant texting platform is linked to the Fitbit Application Program Interface. Real-time activity data will be transmitted from the subject's smartphone to the mHealth platform via cellular network.
Study NCT04938648 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist-led deprescribing intervention
Description: 1) direct-to-consumer deprescribing educational materials designed to activate the care partner and people living with dementia PLWD; 2) a telehealth visit in which a clinical pharmacist discusses benefits and harms of the patient's medications with the patient and care partner in the context of their goals and preferences; and 3) pharmacist-PCP communication in which the pharmacist provides tailored deprescribing recommendations designed to be useful and actionable for the PCP
Study NCT04938648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist-led deprescribing intervention
Description: 1) direct-to-consumer deprescribing educational materials designed to activate the care partner and people living with dementia PLWD; 2) a telehealth visit in which a clinical pharmacist discusses benefits and harms of the patient's medications with the patient and care partner in the context of their goals and preferences; and 3) pharmacist-PCP communication in which the pharmacist provides tailored deprescribing recommendations designed to be useful and actionable for the PCP
Study NCT06486831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Squeeze the stress ball.
Description: The child and parents will be taken to the procedure room for the casting procedure. The plastering process in children takes an average of 10-15 minutes. In the experimental group, the stress ball selected by the child will be started 1-2 minutes before the casting process and will be watched for an average of 10 minutes. If the procedure is prolonged, the time for squeezing and playing with the stress ball will be extended.
Study NCT05213169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apomorphine Hydrochloride 5mg/ml
Description: Product administered using an external continuous subcutaneous infusion pump.
Study NCT05213169 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride 9mg/ml
Description: Product administered using an external continuous subcutaneous infusion pump.
Study NCT05819892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given by IV (vein)
Study NCT05819892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given by IV (vein)
Study NCT05819892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Given by IV (vein)
Study NCT05819892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given by IV (vein)
Study NCT06122584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PSMA-1007
Description: Diagnostic radiopharmaceutical for PET scan
Study NCT04788264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Receive Fitbit
Study NCT04788264 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device Usage and Evaluation
Description: Receive Fitbit
Study NCT04788264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consultation
Description: Receive consultation from a physical therapist
Study NCT04788264 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Consultation
Description: Receive consultation from a physical therapist
Study NCT04788264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Attend exercise training sessions
Study NCT04788264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Attend sessions with a behavioral therapist
Study NCT04788264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04788264 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04788264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Assessment
Description: Ancillary studies
Study NCT04788264 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Life Assessment
Description: Ancillary studies
Study NCT05528952 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atezolizumab
Description: 1200 mg IV every 3 weeks until disease progression or unacceptable toxicity
Study NCT05528952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg IV every 3 weeks until disease progression or unacceptable toxicity
Study NCT05528952 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: 15 mg/kg IV every 3 weeks until disease progression or unacceptable toxicity
Study NCT05528952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg IV every 3 weeks until disease progression or unacceptable toxicity
Study NCT05528952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCPVax
Description: UCPVax vaccine (combined with Montanide ISA51 as adjuvant) at 0.5 mg subcutaneously
Study NCT06479785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention Program for machine workers
Description: A detailed Educational Intervention Program for marble factory workers working on Machines.
Study NCT06479785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention Program for manual workers
Description: A detailed Educational Intervention Program for marble factory workers working manually.
Study NCT05482243 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: Throughout 1 week (either in week 1 or 2), all participants will perform a 1-week resistance type exercise-training program, consisting of two different exercises. Leg press and leg extension exercise will be performed on regular weightlifting machines (Technogym, Rotterdam) at 3 days during the 1-week period (e.g. Monday-Wednesday-Friday). During the resistance exercise training protocol, participants will continue their habitual diet as usual. However, patients with CKD will be provided with a protein supplement following the exercise sessions.
Study NCT05249166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ALINFA
Description: Comparing the usual recommendations with the healthy diet designed and developed
Study NCT05249166 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: control group
Study NCT05438108 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab
Description: SBRT Sequential CapeOX Regimen Chemotherapy Combined With Bevacizumab and Sintilimab
Study NCT05180825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Mekinist© (Trametinib) taken orally each day with a 18-course schedule of 4 weeks each.
Study NCT05180825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinblastine
Description: weekly intra-venous Vinblastine (Velbe©) during 18 courses of 4 weeks each
Study NCT04921098 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diode Laser Cyclophotocoagulation
Description: A handpiece (G probe) is used to deliver the diode laser energy with a wavelength of 810 nm.
Study NCT05605145 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PCR was used to detect pneumocystis in respiratory specimens
Description: Respiratory tract specimens such as alveolar lavage fluid, sputum and throat swabs were collected from all patients who met the enrollment conditions of this study. qPCR and/or mNGS were used to detect pneumocystis in respiratory specimens.
Study NCT05420363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: different walking surfaces
Description: different surfaces materials and textures as sand ,grass, air mattress , foam mattress ,gravels and Rollator
Study NCT05420363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional gait training over hard surface only
Description: The children will receive gait training over hard surface and even ground only and bare feet without wearing any foot ware or orthosis
Study NCT05541315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-88260237
Description: JNJ-88260237 will be administered orally.
Study NCT05541315 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered orally.
Study NCT05877677 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: consume 1 bottle per day
Study NCT05877677 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polygonatum kingianum extract drink
Description: consume 1 bottle per day
Study NCT05349513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESSME questionnaire
Description: The experimental ecological questionnaire ESSME is administered 7 to 14 days after the inclusion visit and 7 to 14 days after the 6 months follow-up visit to the patient at their home.
Study NCT06742645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Interviewing
Description: Brief Motivational Interviewing (BMI), the object of the training and of the present research study, is an interview methodology that includes the intervention on the motivation to change of subjects with risky behaviors for their health, in order to obtain changes in their lifestyle and maintain correct behaviors for health over time (1). The BMI is mainly based on the Transtheoretical Model of Change by Di Clemente CC. and Prochaska JO (2).~In particular, the BMI has been defined by its creators, Miller and Rollnick, as a collaborative style of conversation aimed at strengthening motivation and commitment to change (3), both through defined attitudes, strategies and techniques, and through the exploration of ambivalence or internal fracture, which together with availability and a sense of self-efficacy (4) provides a framework of personal motivation.
Study NCT06742645 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: Standard of Care (SOC) - The health workers of the Navile Community House carry out the outpatient visit and after having identified the health problems they propose a possible treatment. The users belonging to the control arm will complete the SF-36 questionnaire
Study NCT04626050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Music
Description: Participants randomized to this condition will complete 4 medical music sessions over the course of 2 weeks
Study NCT04626050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Writing
Description: Participants randomized to this condition will complete 4 narrative writing sessions over the course of 2 weeks
Study NCT04626050 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure Therapy
Description: Psychotherapy including imaginal exposure for PTSD
Study NCT04626050 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Psychotherapy
Description: Psychotherapy that focuses on the effects of PTSD on current interpersonal functioning
Study NCT04852978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casirivimab+imdevimab
Description: Wave 1 Intravenous (IV) administration Wave 2 Subcutaneous administration
Study NCT04852978 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273 vaccine
Description: Single intramuscular (IM) injection
Study NCT05225415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT1812
Description: Orally administered CT1812
Study NCT05225415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CT1812
Description: Orally administered CT1812
Study NCT06159296 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hydroxy gas
Description: Hydroxy gas is a combination of hydrogen and oxygen together.
Study NCT06338644 — intervention group
Intervention type: DRUG
Intervention: Palbociclib
Description: 3 weeks on, 1 week off
Study NCT06151938 — intervention group
Intervention type: DRUG
Intervention: Standardised allergen extract from house dust mites
Description: Drug: Allergen immunotherapy \[ACARIZAX® (12-SQ HDM) house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet\] for moderate to severe house dust mite allergic rhinitis with or without allergic asthma for 12 months.
Study NCT06438224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Description: Those in the ESWT group were asked to select the most hypertrophic and retracting scars for treatment. ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen, Switzerland), with an electromagnetic cylindrical coil source used to focus the shock wave. ESWT was performed around the primary treatment site, at an intensity of 100 impulses/cm2, an energy flux density (EFD) of 0.05 to 0.30 mJ/mm2, and frequency of 4 Hz. Regarding the volume of treatment, 1000-3000 impulses were administered per session for 12 sessions held at 1-week intervals.
Study NCT06165874 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NOTA-RW102 PET Imaging
Description: Intravenous injection of 1.8 MBq\[0.05MCi\]/kg of \[68Ga\]Ga-NOTA-RW102 in a single dose.
Study NCT06789471 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: psyllium husk
Description: Psyllium husk, derived from the seeds' husks of the Plantago ovata plant, is a plant-based fiber supplement.
Study NCT05734066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Administered as intravenous (IV) infusion once every 3 weeks (Q3W)
Study NCT06112171 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intravascular lithotripsy
Description: Lesion preparation with Shockwave Medical Peripheral Lithotripsy System
Study NCT06112171 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard lesion preparation
Description: Lesion preparation with Standard and/or High-Pressure Balloon Angioplasty
Study NCT06112925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Therapy Management
Description: The medication therapy management intervention was delivered via the five (5) core components which include medication therapy review, personal medication record, medication-related action plan, intervention, and documentation and follow-up. The interventions was also given via educating patients about diabetes, hypertension, complications of diabetes and hypertension, impact of having diabetes and hypertension, antidiabetes and antihypertensive medications, goals of therapy for diabetes and hypertension, health promoting behaviours (healthy diet, regular exercise, salt reduction, \& smoking cessation), drug adherence, and self-monitoring of the diseases.
Study NCT06438224 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: the sham group was treated using an adapter that had the same shape but did not emit any energy
Study NCT05948683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: The stimulant MDMA
Study NCT05948683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dextrose
Study NCT06323239 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT for metastatic lesions
Study NCT05041738 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoral Cryotherapy
Description: small ice packs wrapped in sterile gauze placed in the mouth on the vestibular surface of the treated tooth
Study NCT05041738 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intracanal Cryotherapy
Description: Intracanal cryotherapy technique using 2.5°C cold saline irrigation as final irrigant
Study NCT06323239 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose Radiotherapy (LDRT)
Description: LDRT for metastatic lesions
Study NCT06323239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 6 cycles for combined therapy. Toripalimab maintenance for 1 year.
Study NCT06323239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 6 cycles for combined therapy.
Study NCT06323239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 6 cycles for combined therapy.
Study NCT06323239 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: IMRT for primary lesion
Study NCT04927013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message-based Outreach Intervention for Survivors
Description: The Georgia Cancer Registry will mail the initial recruitment containing messages intended to persuade the survivor to visit the study website as well as a unique login to access the website. In addition to the components of the standard website, an expanded website for the Message-based group will include Guidance for Talking with Close Relatives about Their Cancer Risk, and the request to enumerate each close relative and choose from a menu of options about how the survivor would prefer for their relatives to be contacted. Survivors also can select the option that they prefer a relative not be contacted. In this case, no invitation letter will be generated for these relatives. Survivors who provide mobile phone numbers will receive two SMS thanking them for accessing the website, and encouraging them to revisit the website to review information and contact relatives. The messages will occur at 3-week intervals over a 6-week time period.
Study NCT04927013 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Outreach for Survivors
Description: The Georgia Cancer Registry will mail survivors an introductory letter modeled on the Registry's general outreach letters that will include log in information. Survivors will have access to a condensed version of the website that includes Information about Ovarian Cancer, Information about Who in Your Family is at Increased Risk, and the offer of Free Genetic Counseling with the option to schedule an appointment.
Study NCT04927013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message-based Outreach Intervention for Close Relatives
Description: Relatives will receive a unique website login linked to the survivor that enables access to the website. The website content will be identical to the survivor content with the exception of the addition of the Breast Cancer Genetics Referral Screening Tool (B-RST) risk assessment tool. This brief risk assessment is a validated screening tools that is clinically useful for estimating the probability of breast cancer (BRCA1/2) gene mutation and identifying women for referral to genetic counseling. Although all 1st or 2nd degree relatives of ovarian cancer survivors will screen positive on B-RST, asking relatives to complete the screener aims to raise their awareness of the factors that contribute to hereditary risk of ovarian cancer and will reinforce the salience of seeking genetic counseling. Additionally, relatives for who provide cell phone numbers will receive 3 SMS reminders over 9 weeks.